Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has been given a consensus rating of “Moderate Buy” by the ten analysts that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $11.56.

Several research firms have recently issued reports on MRVI. Craig Hallum initiated coverage on shares of Maravai LifeSciences in a report on Wednesday, April 10th. They set a “buy” rating and a $15.00 price objective on the stock. Stifel Nicolaus lowered their price target on shares of Maravai LifeSciences from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, February 23rd. Finally, Royal Bank of Canada raised their price target on shares of Maravai LifeSciences from $12.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, February 23rd.

Hedge Funds Weigh In On Maravai LifeSciences

A number of institutional investors have recently modified their holdings of the company. Signaturefd LLC raised its stake in shares of Maravai LifeSciences by 99.9% in the third quarter. Signaturefd LLC now owns 3,364 shares of the company’s stock valued at $34,000 after buying an additional 1,681 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of Maravai LifeSciences by 96.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,391 shares of the company’s stock worth $34,000 after acquiring an additional 1,662 shares in the last quarter. Gladius Capital Management LP bought a new stake in Maravai LifeSciences in the fourth quarter worth $30,000. Performa Ltd US LLC boosted its holdings in Maravai LifeSciences by 112.4% during the 4th quarter. Performa Ltd US LLC now owns 6,000 shares of the company’s stock valued at $39,000 after acquiring an additional 3,175 shares during the period. Finally, Pinnacle Associates Ltd. bought a new position in shares of Maravai LifeSciences in the fourth quarter worth approximately $69,000. 50.25% of the stock is owned by institutional investors and hedge funds.

Maravai LifeSciences Price Performance

Shares of NASDAQ MRVI opened at $8.97 on Monday. The firm’s 50-day simple moving average is $8.04 and its 200 day simple moving average is $6.69. The stock has a market cap of $2.26 billion, a P/E ratio of -9.97 and a beta of 0.03. The company has a quick ratio of 7.41, a current ratio of 8.00 and a debt-to-equity ratio of 0.70. Maravai LifeSciences has a fifty-two week low of $4.52 and a fifty-two week high of $16.62.

Maravai LifeSciences (NASDAQ:MRVI) last released its earnings results on Thursday, February 22nd. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The firm had revenue of $74.14 million during the quarter, compared to analysts’ expectations of $62.99 million. Maravai LifeSciences had a negative return on equity of 1.31% and a negative net margin of 41.19%. Equities analysts expect that Maravai LifeSciences will post -0.15 EPS for the current year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.